Knight Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CAD 86.6 million compared to CAD 82.6 million a year ago. Net loss was CAD 4.55 million compared to CAD 3.94 million a year ago.

Basic loss per share from continuing operations was CAD 0.04 compared to CAD 0.04 a year ago. Diluted loss per share from continuing operations was CAD 0.04 compared to CAD 0.04 a year ago.